Drug Search Results
More Filters [+]

KRN-5500

Alternative Names: krn-5500, krn5500, krn 5500
Latest Update: 2022-03-28
Latest Update Note: News Article

Product Description

treatment of neuropathic pain in patients with cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00474916)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: DARA BioSciences|Midatech Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KRN-5500

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Neuropathic Pain|Neuralgia

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DTCL100

P2

Completed

Neuralgia|Neuropathic Pain

2009-03-01

NCI-2012-03132

P1

Completed

Oncology Solid Tumor Unspecified

2008-11-01

NSC650426

P1

Completed

Oncology Solid Tumor Unspecified

2000-01-01

Recent News Events